Survey on Chronic Respiratory Diseases at the PrimaryHealth Care Level

Similar documents
BACPR Annual Conference Generic versus Specialist Rehabilitation FOR

Chronic respiratory diseases at primary health care level in Georgia: the results of the pilot study

COPD, Asthma, Or Something In Between? Sharon R. Rosenberg Assistant Professor of Medicine Northwestern University December 4, 2013

Direct and indirect CV effects of current drugs and those in development

This is a cross-sectional analysis of the National Health and Nutrition Examination

Commissioning for Better Outcomes in COPD

Asthma Tutorial. Trainer MRW. Consider the two scenarios, make an attempt at the questions, what guidance have you used?

Pulmonary Rehabilitation in Chronic Lung Disease; Components and Organization. Prof. Dr. Müzeyyen Erk Cerrahpaşa Medical Faculty Chest Disease Dept.

COPD in Korea. Division of Pulmonary, Allergy and Critical Care Medicine of Hallym University Medical Center Park Yong Bum

Roflumilast (Daxas) for chronic obstructive pulmonary disease

American Thoracic Society (ATS) Perspective

Guideline for the Diagnosis and Management of COPD

Screening and Referral. Unit: Programming Pilates Matwork

Online Data Supplement. Prevalence of Chronic Obstructive Pulmonary Disease in Korea: Results of a Population-based Spirometry Survey

National COPD Audit Programme

JOINT CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MANAGEMENT GUIDELINES

NAME: DATE: SCHOOL/ORGANISATION:

Changing Landscapes in COPD New Zealand Respiratory Conference

Managing Bronchial Asthma in Primary Health Care (PHC) in Syria as Example of Middle Income Developing Country: An Expert Opinion

Self-management plan for COPD

The State of Asthma in Arkansas

BTS Guideline for Home Oxygen use in adults Appendix 9 (online only) Key Questions - PICO 10 December 2012

รศ. นพ. ว ชรา บ ญสว สด M.D., Ph.D. ภาคว ชาอาย รศาสตร คณะแพทยศาสตร มหาว ทยาล ยขอนแก น

COPD-Related Musculoskeletal Disease. Jessica Bon Field, MD, MS 2017 Update in Internal Medicine October 20, 2017

UNDERSTANDING COPD MEDIA BACKGROUNDER

Bronchiectasis Domiciliary treatment. Prof. Adam Hill Royal Infirmary and University of Edinburgh

COPD UPDATE ıdr Shitrit David ıhead of the Pulmonary Department ımeir Medical Center

QOF indicator area: Chronic Obstructive Pulmonary disease (COPD)

Helping TB patients quit smoking: the potential impact, WHO recommendations and country experience

Dr B. Egger Service de Pneumologie Hôpital de Rolle

Activities and Plans of GARD Korea

Statins in lung disease

Information Management. A System We Can Count On. Chronic Conditions. in the Central East LHIN

Defining COPD. Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist

Sarcoidosis Registry Proforma

Asthma and COPD in older people lumping or splitting? Christine Jenkins Concord Hospital Woolcock Institute of Medical Research

Cardiac & Pulmonary Rehab Individual Treatment Plan

Life-long asthma and its relationship to COPD. Stephen T Holgate School of Medicine University of Southampton

TORCH: Salmeterol and Fluticasone Propionate and Survival in COPD

Productivity losses in chronic obstructive pulmonary disease a population-based survey.

National COPD Audit Programme

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Synergy Respiratory Care Dr. Lyle Melenka

2/4/2019. GOLD Objectives. GOLD 2019 Report: Chapters

Using Pay-for-Performance to Improve COPD Care MHC64474 SV64474

Chronic Obstructive Pulmonary Disease

A systematic approach to asthma managament. Finnish Asthma Programme

The local healthcare system: Focusing on health

REPORT FROM THE CANADIAN CHRONIC DISEASE SURVEILLANCE SYSTEM:

Sydney, AUSTRALIA Beijing, CHINA Hyderabad, INDIA Oxford, UK. Affiliated with

COPD as a comorbidity of heart failure in elderly patients

Ministry of Health Kyrgyz Republic. National Center Cardiology and Internal Medicine. GARD in Kyrgyzstan. Talant M. Sooronbaev.

Looking Toward State Health Assessment.

Fort Ha milton Hospital. Community Benefit Plan & Implementation Strategy

Texas Chronic Disease Burden Report. April Publication #E

Course Handouts & Disclosure

Chronic conditions, physical function and health care use:

Epidemiology of chronic diseases in developing countries. Prof Isaac Quaye, UNAM SOM

Chronic Obstructive Pulmonary Disease (COPD).

Why Non communicable Diseases? Why now?

Differential diagnosis

The Aging Lung. Sidney S. Braman MD FACP FCCP Professor of Medicine Brown University Providence RI

How to treat COPD? What is the mechanism of dyspnea? Smoking cessation

Three triggers that suggest that patients could benefit from a hospice palliative care approach

JUSTUS WARREN TASK FORCE MEETING DECEMBER 05, 2012

Specialist Palliative Care Referral for Patients

Please fill in all bubbles completely! Patient Name: Date: Date of Birth: Referring Doc: Family Doc: I. What are you being seen for today?

well-targeted primary prevention of cardiovascular disease: an underused high-value intervention?

Management of Acute Exacerbations

The Burden of Heart Failure in the Asia Pacific. Eugenio B. Reyes, M.D. Associate Professor, University of the Philippines, College of Medicine

What s new in COPD? Apichart Khanichap MD. Department of Medicine, Faculty of Medicine, Thammasat university

New Horizons. Long Term Conditions

호흡재활치료 울산의대서울아산병원 호흡기내과 이상도

Lessons to be learned from cardiopulmonary rehabilitation

COPD COPD. C - Chronic O - Obstructive P - Pulmonary D - Disease OBJECTIVES

Bronchodilator Delivery and Nebuliser Trials in Adults

ATS 2013 International Conference May Philadelphia Pennsylvania

Pneumococcal pneumonia

Disability and Obesity

Outline FEF Reduced FEF25-75 in asthma. What does it mean and what are the clinical implications?

Chronic respiratory disease: towards better treatments

Reduced lung function in midlife and cognitive impairment in the elderly

Modern Management of COPD.

Asma, BPCO ed Esercizio Fisico Ferrara, 6 e 7 Novembre Overlap asma BPCO. Dr. Marco Contoli

Room # Critical Care & Pulmonary Consultants, P.C.

COPD in primary care: reminder and update

RESPIRATORY MEDICAL CLEARANCE QUESTIONNAIRE

Patient reported outcomes in respiratory diseases; How to assess clinical success in COPD

Brian Carlin, MD Disclosures 4/6/2014. Speakers bureau Glaxo Smith Kline Boehringer Ingelheim Philips Respironics Forest Breathe Technologies PneumRx

Comorbidities in HF COPD Chronic Obstructive Pulmonary Disease Gerasimos Filippatos Athens, Greece

In-Patient Sleep Testing/Management Boaz Markewitz, MD

Rosemary Plum Prescriptive Solutions Ltd SIMPLE Respiratory 2015

EXACERBATION ASSESSMENT FORM

PREDICTION EQUATIONS FOR LUNG FUNCTION IN HEALTHY, LIFE TIME NEVER-SMOKING MALAYSIAN POPULATION

COPD. Salah Zeineldine, MD FACP Pulmonary & Critical Care Medicine American University of Beirut Lebanese Society of Family Medicine 2012

Obstructive Sleep Apnea

TALKING POINTS. Ten Reasons Why the Ozone Air Quality Standard Must Be Strengthened

Global momentum to scale up response to chronic disease burden Need for accurate, timely & comparable data

COPD and environmental risk factors other than smoking. 14. Summary

Chronic Obstructive Pulmonary Disease

Transcription:

Survey on Chronic Respiratory Diseases at the PrimaryHealth Care Level Nikolai Khaltaev MD, PhD GARD General Meeting Istanbul, Turkey, 30-31 May 2008

Burden of major respiratory diseases Respiratory diseases (RD) represent a global public health problem due to high morbidity and mortality, causing almost 17% of all deaths and 12% of the global burden of diseases

Burden of Major Respiratory Diseases Diseases Deaths DALY s % % Lower Respiratory Infections 6,8 6,1 COPD 4,8 1,9 Tuberculosis 2,7 2,3 Lung/Bronchus/Trachea Cancer 2,2 0,8 Asthma 0,4 1,0 Total 16,9 12,1 DALY s = Disability-Adjusted Life-Years Source: World Health Report 2004

RD prevalence data Could be received based on the population surveys within the community or the surveys at PHC level.

Population based survey Community, population based screening in epidemiological surveys measures the frequency and distribution of the diseases in order to identify the geographical distribution of the diseases and risk factors, need and impact of intervention and monitoring time trends. It is well suitable for a single disease.

PHC survey For a group of diseases like RD which are both chronic and acute, infectious and noninfectious this approach is not suitable from the practical point of view and in particular in developing countries, where the need to organize at least four vertical surveys in population is not realistic due to multiple reasons (cost, huge population sample, screening time etc). PHC survey is the only way to address this issue

CRD at Primary Health Care Level Primary health care is a backbone of the health care systems in many countries. It very often constitutes a first contact point with health professionals for majority of patients.

CRD at Primary Health Care Level At PHC level, assessment of prevalence of RD, their risk factors status, and early diagnosis are vital not only for development of the prevention and control programme but also for the evaluation of patients flow, health professionals workload, calculation of the need of specialists, equipments and drugs. This will also allow planning and initiation of a comprehensive training and workforce development programmes.

CRD at Primary Health Care Level Based on the WHO survey in Jordan, Kyrgyzstan, Argentina, Morocco, Guinea, Nepal and Thailand RD represent from almost 10 to about 40% of all admissions to PHC

CRD at primary Health Care Level Lack of awareness of CRD and in particular of COPD, commonality of symptoms with infectious respiratory and other chronic diseases lead to dramatic under diagnosis of CRD, wrong treatment and wrong referral especially in low and middle income countries.

CRD at Primary Health Care Level Obtaining of relevant data on the most prevalent RD and their risk factors is one of the major GARD's objectives.

Rationale Two are the questions of research, which deserve to be prioritised in the context of the assessment of the prevalence of major respiratory diseases, in particular in middle and low income countries.

Rationale On the one hand there is a demand for the assessment of the prevalence and the severity of respiratory diseases to develop prevention and control programme

Rationale on the other hand, a need to know the under-diagnosis and management associated with them there to assess the need of specialists, equipment and drugs

Why PHC? For practical reasons, it is recommended to estimate the prevalence of respiratory diseases at the Primary Health Care level.

Why PHC? Compared to a survey at the general population level, a survey at the PHC level offers the following advantages: reduced costs, reduced time and a simpler follow-up of the patients through the GP and other health care workers network.

Emergency departments data To complete the data, as it is usual in many countries that patients attend directly emergency room (ER) departments for their respiratory troubles without being referred by the general practitioner (GP), data from Emergency Room (ER) should be also collected.

Specific objectives of the PHC survey To assess reported prevalence and severity of major respiratory diseases at the primary health care level. This will be validated in a sub-sample of individuals by lung function testing. To determine spirometric values in a sub-sample of individuals drawn from the consultants of PHC. To identify factors associated with respiratory diseases To assess prevalence of major respiratory diseases at the ER departments.

Management of Respiratory Diseases at the Primary Health Care level. Specific objectives: To evaluate the management of respiratory diseases at the primary health care level. To estimate the under-and over-diagnosis and the under and over-treatment of respiratory diseases at the primary health care level.

2. Situation analysis GARD runs pilot projects on surveillance of chronic respiratory diseases at primary health care level Georgia Russian Federation Cape Verde Philippines

Distribution of the main symptoms (%) in two regions of Georgia 30 25 26.9 20 15 18.6 10 5 0 4.9 4.5 6.4 4.4 0.3 Cough Wheezing BA Mtskheta Sagarejo Official data

Distribution of the main symptoms (%) 14 12 10 8 10.2 10 11.1 12.8 6 4 2 0 4.3 0.47 1.4 Chr. bronch. TB Allergy Mtskheta Sagarejo Official data

Prevalence of concomitant cardiovascular diseases in chronic respiratory disease patients ( % ) Males Females 60 50 40 ( % ) 30 20 10 0 `15-49 years Age of patients `50 years and over

Possible COPD Based on Symptoms(Cough, Phlegm, or Breathlessness) In population >40 years (N=951) E1: Do you usually have a cough this last 1 months? E2. Do you usually bring up phlegm from your chest? E3.1 Are you troubled by shortness of breath when hurrying on the level or walking up slight hill? Age (years) COPD(%) 40-49 28.9 50-59 35.2 60-69 41.1 70-55.2 Total 36.7 Preliminary Data

Estimated prevalence of hospital discharges with selected comorbidities in patients with and without COPD White bars show patients without any mention of a COPD dischargediagnosis. IHD ischemic heart disease; CHF congestive heart failure; RF respiratory failure; PVD pulmonary vascular disease; TM thoracic malignancy. Chest 2005;128;2005-2011

COEXISTING ILLNESSES in a clinical study of COPD Vascular (including hypertension) 64% Cardiac 38% Gastrointestinal 48% Musculoskeletal or connective tissue 46% Metabolic or nutritional 47% Reproductive or urinary 27% Neurological 22% Niewoehner et al, Ann Intern Med. 2005;143:317-326

Cardiovascular mortality in COPD For every 10% decrease in FEV 1, cardiovascular mortality increases by approximately 28% and non-fatal coronary event increases by approximately 20% Anthonisen et al, Am J Respir Crit Care Med 2002

Increased levels of inflammatory markers in patients with COPD 160 140 * Healthy subjects COPD patients * 2.0 120 1.5 100 80 60 40 20 0 IL-8 (pg/ml) * C reactive protein (µg/ml) * LPS binding protein (µg/ml) s-tnf-r55 (ng/ml) s-tnf-r75 (ng/ml) 1.0 0.5 0.0 Schols AMW et al. Thorax 1996; 51: 819-24

Cardiovascular morbidity in COPD Longitudinal investigations Systemic inflammation predicts Death Heart disease Acc fall in FEV 1 Sin and Man, Circulation 2003

ischaemic cardiac events in patients with COPD and treatment with budesonide 800µg day 1 ( ) or placebo ( ) for up to 3yrs. Eur Respir J 2007; 29:1115-1119

Statin Use Reduces Decline in Lung Function Neutrophil inflammation? Oxidative stress? AJRCCM 2007,176: 742-7

FEV1 and risk of CNS-stroke Truelsen T et al Int J Epidemiol 2001

Conclusion The survey data are directly applicable in countries with PHC based health care systems. Health professionals and administrators will know the number of patients with RD and accompanying risk factors, the level of control and treatment of RD and their risk factors, number of patients needed hospitalization and rehabilitation. Health administrators will be able to assess the drugs, equipment and oxygen supply depending on the disease prevalence and severity, number of health professionals and hospital and intensive care beds for severe cases.

Conclusion Identification of the number of people at risk of development of RD will help to identify the cohorts for the preventive strategy based on the reduction or elimination of the risk factors. In view of the commonality of the RD risk factors (smoking, air pollution, unhealthy diet, malnutrition from one side obesity and overweight from the other side, low physical activity etc) with the risk factors of major chronic diseases (cardiovascular, certain types of cancer, diabetes, osteoporosis and others) the RD prevention will be beneficial not only for these group of diseases but also for other major chronic diseases and for the health of the whole population.

PHC survey and awareness on major CRD Finally the survey will improve the awareness on major RD, estimate the burden of RD which is certainly many folds higher than currently believed based on the official health statistics which register mainly severe cases of the diseases (in particular COPD) and dramatically underestimate the real prevalence leaving many patients undiagnosed and untreated or undertreated. It will enhance early detection of RD and promote better management according to existing guidelines based on the available and affordable therapies.